The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2024 | Investigating resistance mechanisms to bispecific antibodies and CAR-T in patients with lymphoma
Pau Abrisqueta, MD, PhD, Vall d´Hebron University Hospital, Barcelona, Spain, briefly discusses a hot topic in the field of hematological oncology: resistance to bispecific antibodies and CAR T-cell therapy. Further investigation is needed into the different mechanisms of resistance that exist, such as how the intrinsic biological factors of the lymphoma may mediate the development of resistance in patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
